

Supporting Information

Microwave-assisted palladium mediated efficient synthesis of pyrazolo[3,4-*b*]pyridines, pyrazolo[3,4-*b*]quinolines, pyrazolo[1,5-*a*]pyrimidines and pyrazolo[1,5-*a*]quinazolines

Kommuri Shekarrao,^a Partha Pratim Kaishap,^a Venkateshwarlu Saddanapu,^b Anthony Addlagatta,^b Sanjib Gogoi,^{a*} Romesh C Boruah^{a*}

* Corresponding author, Tel.: +91 3762372948; fax: +913762370011; skgogoi1@gmail.com; rc_boruah@yahoo.co.in

^aMedicinal Chemistry Division, North-East Institute of Science and Technology, Jorhat, Assam 785 006, India

^bCenter for chemical biology, CSIR-IICT, Tarnaka, Hyderabad, AP-500 607

Table of Contents

- (1) General Information
- (2) Microwave Instrumentation
- (3) General procedure for the synthesis of pyrazolo[3,4-*b*]pyridines (**3a-m**) and pyrazolo[3,4-*b*]quinolines (**3n-p**) under microwave irradiation
- (4) Characterization data for compounds **3a-p**
- (5) General procedure for the synthesis of pyrazolo[1,5-*a*]pyrimidines (**6a-h**) and pyrazolo[1,5-*a*]quinazolines (**6i-k**) under microwave irradiation
- (9) Characterization data for compounds **6a-k**
- (10) Procedure for the preparation of compound **6l** and its characterization data
- (11) MTT assay protocol
- (12) ¹H and ¹³C spectra for compounds **3a-p** and **6a-l**

General Information

Melting points were measured with a Buchi B-540 melting point apparatus and are uncorrected. IR spectra were recorded on Elmer FT-IR-2000 spectrometer on a thin film using chloroform. NMR spectra were recorded on Avance DPX 300 MHz FT-NMR spectrometer or Bruker Avance III 500 MHz FT-NMR spectrometer using tetramethylsilane (TMS) as an internal standard. Mass spectra were recorded on Trace DSQ GCMS instrument. All the commercially available reagents were used as received. All experiments were monitored by thin layer chromatography (TLC). TLC was performed on pre-coated silica gel plates (Merck). Column chromatography was performed on silica gel (100-200 mesh, Merck). All MW reactions were carried out in a Synthos 3000 (Anton Paar) microwave reactor.

Microwave Instrumentation

All microwave reactions were carried out in a Synthos 3000 (Anton Paar) microwave reactor. The multitude microwave has a twin magnetron (2.45 GHz) with maximum output power of 1400 W. The output power can be controlled in unpulsed control mode over whole power which is adjustable in 1 W increment. A Motorola 68xxx series microprocessor system control is used to measure power, pressure, time and temperature during the reaction. The temperature and pressure were monitored throughout the reaction by an infrared detector. The temperature can be measured from 0 to 280 °C with uncertainty $\pm 1\%$. The temperature during the MW reaction was monitored by an externally calibrated IR sensor. The pressure can be measured from 0 to 86 bar with uncertainty ± 0.2 bar. The MW power is initially set at 700 W and the reaction is run. However, during the course of the reaction, once the set temperature and pressure limit is reached, the reactor automatically adjusts the power by lowering it.

General procedure for the synthesis of compounds 3a-p: A mixture of halo aldehyde (**1**, 1.0 mmol), 5-aminopyrrazole (**2**, 1.2 mmol), Pd(OAc)₂ (2.5 mol%), PPh₃ (5 mol%) and K₂CO₃ (2.1 mmol) was irradiated in a closed vessel in a Synthos 3000 microwave reactor at 700 Watt (120 °C and 14 bar) for 15 minutes. After completion of the reaction, the reaction mixture was treated with water (40 mL) and then extracted with ethylacetate (30 x 3 mL). The organic portion was washed with water, dried over anhydrous sodium sulfate and the solvent was removed in vacuo to obtain a crude product which on silica gel column chromatographic purification using EtOAc/hexane as the eluent afforded compounds **3a-p**.

3-Methoxy-8-methyl-10-phenyl-6,10-dihydro-5H-benzo[h]pyrazolo[3,4-b]quinoline (**3a**): Yellow solid, mp: 162-163 °C. ¹H NMR (CDCl₃, 300 MHz) δ 8.43 (d, *J* = 7.6 Hz, 2H), 8.38

(d, $J = 8.7$ Hz, 1H), 7.70 (s, 1H), 7.52 (t, $J = 7.4$ Hz, 2H), 7.23 (t, $J = 5.1$ Hz, 1H), 6.93 (dd, $J = 8.6$ Hz & 2.6 Hz, 1H), 6.75 (d, $J = 2.5$ Hz, 1H), 3.86 (s, 3H), 3.02-2.98 (m, 2H), 2.95-2.89 (m, 2H), 2.59 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz) δ 160.8, 152.5, 150.5, 142.2, 141.1, 140.1, 128.9, 127.8, 127.7, 127.6, 125.1, 124.8, 120.2, 120.1, 115.5, 112.9, 112.8, 55.3, 29.0, 28.8, 12.5. IR (CHCl_3 , cm^{-1}): 2932, 1599, 1505, 1381, 1242, 754. MS (EI, m/z): 341.2 [M^+]. Anal. calcd. for $\text{C}_{22}\text{H}_{19}\text{N}_3\text{O}$: C, 77.40; H, 5.61; N, 12.31. Found: C, 77.27; H, 5.76; N, 12.40.

10-Ethyl-3-methoxy-6,10-dihydro-5H-benzo[*h*]pyrazolo[3,4-*b*]quinoline (3b): Yellow solid, mp: 59-60 °C. ^1H NMR (CDCl_3 , 300 MHz) δ 8.43 (d, $J = 8.6$ Hz, 1H), 7.88 (s, 1H), 7.75 (s, 1H), 6.93 (dd, $J = 8.6$ Hz & 2.6 Hz, 1H), 6.77 (d, $J = 2.5$ Hz, 1H), 4.62 (q, $J = 7.3$ Hz, 2H), 3.86 (s, 3H), 3.04-2.97 (m, 4H), 2.94-2.89 (m, 2H), 1.57 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (CDCl_3 , 75 MHz) δ 160.8, 152.1, 149.7, 141.3, 131.1, 127.9, 127.8, 127.5, 125.1, 114.1, 112.9, 112.8, 55.3, 41.9, 29.1, 28.9, 15.0. IR (CHCl_3 , cm^{-1}): 2933, 1601, 1416, 1266, 780. MS (EI, m/z): 279.1 [M^+]. Anal. calcd. for $\text{C}_{17}\text{H}_{17}\text{N}_3\text{O}$: C, 73.10; H, 6.13; N, 15.04. Found: C, 73.12; H, 6.13; N, 15.08.

3-Methoxy-8,10-diphenyl-6,10-dihydro-5H-benzo[*h*]pyrazolo[3,4-*b*]quinoline (3c): Yellow solid, mp: 192-193 °C. ^1H NMR (CDCl_3 , 300 MHz) δ 8.54 (d, $J = 7.8$ Hz, 2H), 8.42 (d, $J = 8.6$ Hz, 1H), 8.11 (s, 1H), 8.05 (d, $J = 7.2$ Hz, 1H), 7.59-7.23 (m, 7H), 6.96 (dd, $J = 8.6$ Hz & 2.5 Hz, 1H), 6.78 (d, $J = 2.3$ Hz, 1H), 3.87 (s, 3H), 3.11-3.05 (m, 2H), 2.99-2.81 (m, 2H). ^{13}C NMR (CDCl_3 , 75 MHz) δ 160.9, 152.6, 151.1, 143.7, 141.3, 140.1, 133.2, 128.9, 128.8, 128.6, 128.4, 127.8, 127.6, 127.2, 126.3, 125.4, 120.8, 113.8, 113.1, 112.9, 55.4, 28.97, 28.9. IR (CHCl_3 , cm^{-1}): 1598, 1497, 1380, 1245, 755. MS (EI, m/z): 403.1 [M^+]. Anal. calcd. for $\text{C}_{27}\text{H}_{21}\text{N}_3\text{O}$: C, 80.37; H, 5.25; N, 10.41. Found: C, 80.45; H, 5.29; N, 10.72.

10-Ethyl-6,10-dihydro-5H-benzo[*h*]pyrazolo[3,4-*b*]quinoline (3d): Red solid, mp: 68 °C. ^1H NMR (CDCl_3 , 300 MHz) δ 8.35 (s, 1H), 8.29 (s, 1H), 8.01 (d, $J = 7.6$ Hz, 1H), 7.40-7.17 (m, 3H), 4.54 (q, $J = 7.2$ Hz, 2H), 2.92-2.79 (m, 4H), 1.48 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (CDCl_3 , 75 MHz) δ 150.4, 148.6, 139.3, 136.3, 132.4, 130.9, 129.6, 128.5, 127.3, 127.2, 125.0, 111.6, 53.5, 28.8, 25.4, 15.0. IR (CHCl_3 , cm^{-1}): 2930, 1561, 1260, 1023, 772. MS (EI, m/z): 249.1 [M^+]. Anal. calcd. for $\text{C}_{16}\text{H}_{15}\text{N}_3$: C, 77.08; H, 6.06; N, 16.85. Found: C, 77.19; H, 5.85; N, 16.70.

8-Methyl-10-phenyl-6,10-dihydro-5H-benzo[*h*]pyrazolo[3,4-*b*]quinoline (3e): Yellow solid, mp: 152 °C. ^1H NMR (CDCl_3 , 300 MHz) δ 8.44 (dd, $J = 7.9$ Hz & 1.2 Hz, 2H), 7.73 (s, 1H), 7.54-7.21 (m, 7H), 3.05-2.91 (m, 4H), 2.59 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz) δ 152.4, 150.5, 142.2, 140.1, 139.3, 134.8, 129.6, 128.9, 127.9, 127.2, 126.8, 126.3, 125.9, 124.9, 120.2, 116.1, 28.7, 28.6, 12.6. IR (CHCl_3 , cm^{-1}): 2925, 1599, 1504, 1411, 1381, 1126, 761.

MS (EI, m/z): 311.1 [M^+]. Anal. calcd. for $C_{21}H_{17}N_3$: C, 81.00; H, 5.50; N, 13.49. Found: C, 81.35; H, 5.58; N, 13.71.

*10-Ethylchromeno[4,3-*b*]pyrazolo[4,3-*e*]pyridin-6(10*H*)-one (3f)*: White solid, mp: 178 °C. 1H NMR ($CDCl_3$, 300 MHz) δ 9.01 (s, 1H), 8.16 (s, 1H), 7.19- 8.63 (m, 4H), 4.63 (q, J = 6.0 Hz, 2H), 1.55 (t, J = 6.0 Hz, 3H). ^{13}C NMR ($CDCl_3$, 75 MHz) δ 161.8, 152.7, 151.2, 150.4, 134.9, 134.2, 132.4, 125.1, 124.7, 119.6, 117.3, 116.2, 111.9, 42.4, 29.7. IR ($CHCl_3$, cm^{-1}): 1728, 1612, 1424, 1170, 750. MS (EI, m/z): 265.0 [M^+]. Anal. calcd. for $C_{15}H_{11}N_3O_2$: C, 67.92; H, 4.18; N, 15.84. Found: C, 67.82; H, 4.37; N, 15.68.

*1-Ethyl-6-phenyl-1H-pyrazolo[3,4-*b*]pyridine (3g)*: Red solid, mp: 62 °C. 1H NMR ($CDCl_3$, 300 MHz) δ 8.06 (d, J = 6.9 Hz, 1H), 8.01 (d, J = 8.4 Hz, 2H), 7.92 (s, 1H), 7.52 (d, J = 8.4 Hz, 1H), 7.48-7.33 (m, 3H), 4.58 (q, J = 7.2 Hz, 2H), 1.51 (t, J = 7.3 Hz, 3H). ^{13}C NMR ($CDCl_3$, 75 MHz) δ 156.3, 150.1, 139.5, 131.6, 130.3, 129.2, 128.8, 128.5, 127.5, 114.4, 114.3, 41.9, 15.0. IR ($CHCl_3$, cm^{-1}): 2930, 1597, 1455, 1440, 927, 758. MS (EI, m/z): 223.1 [M^+]. Anal. calcd. for $C_{14}H_{13}N_3$: C, 75.31; H, 5.87; N, 18.82. Found: C, 75.32; H, 5.81; N, 18.94.

*3-Methyl-1,6-diphenyl-1H-pyrazolo[3,4-*b*]pyridine (3h)*: Red solid, mp: 131 °C. 1H NMR ($CDCl_3$, 300 MHz) δ 8.35 (d, J = 8.5 Hz, 2H), 8.14-8.08 (m, 3H), 8.01 (d, J = 8.3 Hz, 1H), 7.61-6.91 (m, 6H), 2.63 (s, 3H). ^{13}C NMR ($CDCl_3$, 75 MHz) δ 156.8, 151.1, 146.1, 142.6, 139.8, 139.2, 129.9, 128.8, 128.6, 127.6, 126.1, 125.6, 121.1, 120.6, 15.4. IR ($CHCl_3$, cm^{-1}): 1596, 1506, 1261, 799. MS (EI, m/z): 285.1 [M^+]. Anal. calcd. for $C_{19}H_{15}N_3$: C, 79.98; H, 5.30; N, 14.73. Found: C, 80.26; H, 5.35; N, 14.54.

*3 β -Acetoxy-1'-ethyl-androst[16,17-*f*]-1H-pyrazolo[3,4-*b*]pyridine (3i)*: Yellow solid, mp: 167 °C. 1H NMR ($CDCl_3$, 300 MHz) δ 8.34 (s, 1H), 7.43 (s, 1H), 5.44-5.42 (m, 1H), 4.64-4.53 (m, 1H), 4.29 (q, J = 3.9 Hz, 2H), 2.04 (s, 3H), 1.12 (s, 3H), 1.05 (s, 3H), 2.82-0.84 (m, 20H). ^{13}C NMR ($CDCl_3$, 75 MHz) δ 170.6, 157.7, 155.6, 139.9, 138.5, 131.4, 122.3, 73.8, 55.4, 50.5, 46.9, 42.6, 38.1, 36.9, 35.1, 31.6, 30.5, 29.7, 27.7, 21.5, 20.7, 19.3, 16.4, 15.4. IR ($CHCl_3$, cm^{-1}): 1731, 1247, 1030. MS (EI, m/z): 373.2 [$M-60^+$]. Anal. calcd. for $C_{27}H_{35}N_3O_2$: C, 74.79; H, 8.14; N, 9.69. Found: C, 74.88; H, 8.21; N, 9.54.

*3 β -Acetoxy-1',3'-dimethyl-androst[16,17-*f*]-1H-pyrazolo[3,4-*b*]pyridine (3j)*: Yellow solid, mp: 185 °C. 1H NMR ($CDCl_3$, 300 MHz) δ 7.69 (s, 1H), 5.43-5.45 (m, 1H), 4.57- 4.66 (m, 1H), 4.05 (s, 3H), 2.51 (s, 3H), 2.05 (s, 3H), 1.18 (s, 3H), 1.03 (s, 3H), 2.82-0.83 (m, 17H). ^{13}C NMR ($CDCl_3$, 75 MHz) δ 173.9, 170.5, 155.6, 140.1, 139.7, 128.9, 124.5, 122.1, 113.3, 73.8, 56.2, 53.4, 50.5, 45.4, 38.1, 36.9, 33.7, 33.6, 31.9, 31.3, 31.0, 29.7, 29.4, 27.7. IR

(CHCl₃, cm⁻¹): 1733, 1243, 1032. MS (EI, *m/z*): 373.2 [M-60⁺]. Anal. calcd. for C₂₇H₃₅N₃O₂: C, 74.79; H, 8.14; N, 9.69. Found: C, 74.49; H, 8.11; N, 9.82.

3β-Acetoxy-1'-methyl-3'-tert-butyl-androst[16,17-f]-1H-pyrazolo[3,4-b]pyridine (3k):

Yellow solid, 149 °C. ¹H NMR (CDCl₃, 300 MHz) δ 7.82 (s, 1H), 5.32-5.35 (m, 1H), 4.48-4.60 (m, 1H), 3.73 (s, 3H), 1.97 (s, 3H), 1.22 (s, 9H), 1.00 (s, 3H), 0.86 (s, 3H), 2.78-0.80 (m, 17H). ¹³C NMR (CDCl₃, 75 MHz) δ 185.2, 170.6, 160.2, 146.6, 140.0, 122.0, 114.1, 92.2, 73.8, 52.7, 50.4, 46.7, 38.1, 37.0, 36.8, 34.4, 33.9, 32.1, 31.6, 31.3, 31.1, 27.7, 23.7, 21.4, 20.7, 19.4, 16.2. IR (CHCl₃, cm⁻¹): 1733, 1245, 1032. MS (EI, *m/z*): 415.3 [M-60⁺]. Anal. calcd. for C₃₀H₄₁N₃O₂: C, 75.75; H, 8.69; N, 8.83. Found: C, 75.59; H, 8.64; N, 8.78.

3β-Acetoxy-1'-phenyl-3'-methyl-androst[16,17-f]-1H-pyrazolo[3,4-b]pyridine (3l):

Yellow solid, mp: 242 °C. ¹H NMR (CDCl₃, 300 MHz) δ 8.38 (d, *J* = 7.7 Hz, 2H), 7.75 (s, 1H), 7.48 (t, *J* = 7.9 Hz, 2H), 7.23 (t, *J* = 7.4 Hz, 1H), 5.46-5.43 (m, 1H), 4.69-4.55 (m, 1H), 2.61 (s, 3H), 2.05 (s, 3H), 1.12 (s, 3H), 1.05 (s, 3H), 2.81-0.86 (m, 17H). ¹³C NMR (CDCl₃, 75 MHz) δ 174.2, 170.6, 150.7, 142.2, 140.2, 130.2, 128.8, 124.8, 124.7, 122.1, 120.3, 115.5, 73.8, 56.2, 50.6, 45.5, 38.2, 36.9, 33.7, 31.4, 31.1, 30.1, 27.8, 21.5, 20.6, 19.4, 17.5, 12.4. IR (CHCl₃, cm⁻¹): 2931, 1733, 1596, 1508, 1386, 1246, 1028, 773. MS (EI, *m/z*): 435.2 [M-60⁺]. Anal. calcd. for C₃₂H₃₇N₃O₂: C, 77.54; H, 7.52; N, 8.48. Found: C, 77.76; H, 7.68; N, 8.24.

3β-Acetoxy-1'-phenyl-3'-phenyl-androst[16,17-f]-1H-pyrazolo[3,4-b]pyridine (3m):

White solid, mp: 239 °C. ¹H NMR (CDCl₃, 300 MHz) δ 8.50 (d, *J* = 7.8 Hz, 2H), 8.10 (s, 1H), 8.00 (d, *J* = 7.1 Hz, 2H), 7.55- 7.17 (m, 6H), 5.45-5.42 (m, 1H), 4.68-4.56 (m, 1H), 2.05 (s, 3H), 1.11 (s, 3H), 1.05 (s, 3H), 2.84-0.67 (m, 17H). ¹³C NMR (CDCl₃, 75 MHz) δ 174.2, 170.6, 151.2, 143.9, 140.2, 140.1, 133.3, 131.3, 129.1, 128.9, 128.4, 128.2, 127.4, 125.7, 125.4, 122.1, 120.9, 113.9, 73.8, 56.2, 50.5, 45.6, 38.2, 36.9, 33.6, 31.9, 31.3, 31.1, 30.1, 29.7, 27.8, 22.7, 21.4, 20.6, 19.4, 17.5, 14.2. IR (CHCl₃, cm⁻¹): 2929, 1733, 1596, 1504, 1244, 1031, 769. MS (EI, *m/z*): 497.3 [M-60⁺]. Anal. calcd. for C₃₇H₃₉N₃O₂: C, 79.68; H, 7.05; N, 7.53. Found: C, 79.73; H, 7.01; N, 7.79.

1-Ethyl-6-fluoro-1H-pyrazolo[3,4-b]quinoline (3n):

White solid, mp: 97-98 °C. ¹H NMR (CDCl₃, 300 MHz) δ 8.90 (s, 1H), 8.26 (s, 1H), 8.13-8.07 (m, 1H), 7.66-7.61 (m, 1H), 7.56-7.46 (m, 1H), 4.61 (q, *J* = 7.2 Hz, 2H), 1.52 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz) δ 151.4, 146.6, 130.2, 127.3, 125.6, 124.8, 121.3, 113.1, 112.7, 109.5, 42.6, 15.3. IR (CHCl₃, cm⁻¹): 2925, 1588, 1570, 1450, 1239, 955, 772. MS (EI, *m/z*): 215.1 [M⁺]. Anal. calcd. for C₁₂H₁₀FN₃: C, 66.97; H, 4.68; N, 19.52. Found: C, 67.16; H, 4.71; N, 19.61.

1-Ethyl-7-methyl-1H-pyrazolo[3,4-b]quinoline (3o):

Yellow gum. ¹H NMR (CDCl₃, 300 MHz) δ 8.98 (s, 1H), 8.34 (s, 1H), 7.98-7.92 (m, 2H), 7.38 (dd, *J* = 8.3 & 1.1 Hz, 1H), 4.68

(q, $J = 7.3$ Hz, 2H), 2.61 (s, 3H), 1.59 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (CDCl_3 , 75 MHz) δ 152.4, 146.9, 142.4, 130.9, 130.6, 129.1, 127.1, 123.2, 121.9, 42.5, 22.3, 15.3. IR (CHCl_3 , cm^{-1}): 2924, 1634, 1460, 775. MS (EI, m/z): 211 [M^+]. Anal. calcd. for $\text{C}_{13}\text{H}_{13}\text{N}_3$: C, 73.91; H, 6.20; N, 19.89. Found: C, 73.82; H, 6.35; N, 19.70.

1-Ethyl-1H-[1,3]dioxolo[4,5-g]pyrazolo[3,4-b]quinoline (3p): Yellow gum. ^1H NMR (CDCl_3 , 300 MHz) δ 8.82 (s, 1H), 8.26 (s, 1H), 7.36 (s, 1H), 7.32 (s, 1H), 6.15 (s, 2H), 4.66 (q, $J = 7.2$ Hz, 2H), 1.57 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (CDCl_3 , 75 MHz) δ 151.8, 150.5, 146.6, 130.1, 128.6, 121.1, 110.5, 105.6, 101.7, 100.1, 42.4, 15.2. IR (CHCl_3 , cm^{-1}): 2921, 1598, 1457, 1247, 1037, 774. MS (EI, m/z): 241 [M^+]. Anal. calcd. for $\text{C}_{13}\text{H}_{11}\text{N}_3\text{O}_2$: C, 64.72; H, 4.60; N, 17.42. Found: C, 64.79; H, 4.66; N, 17.53.

N-((1-Bromo-6-methoxy-3,4-dihydronaphthalen-2-yl)methylene)-3-methyl-1-phenyl-1H-pyrazol-5-amine (4a): Yellow solid, mp: 142 °C. ^1H NMR (CDCl_3 , 300 MHz) δ 8.96 (s, 1H), 7.73 (d, $J = 7.7$ Hz, 2H), 7.54-7.24 (m, 4H), 7.09 (d, $J = 8.2$ Hz, 1H), 6.83 (dd, $J = 8.2$ Hz & 2.6 Hz, 1H), 6.25 (s, 1H), 3.85 (s, 3H), 2.84-2.72 (m, 4H), 2.37 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz) δ 160.7, 158.5, 150.5, 149.4, 139.4, 136.0, 134.8, 132.9, 130.7, 128.5, 128.2, 126.5, 124.1, 115.4, 114.0, 93.7, 55.5, 26.6, 25.1, 14.2. IR (CHCl_3 , cm^{-1}): 2932, 1594, 1243, 752. MS (EI, m/z): 421 [M^+], 423 [$\text{M} + 2$]. Anal. calcd. for $\text{C}_{22}\text{H}_{20}\text{BrN}_3\text{O}$: C, 62.57; H, 4.77; N, 9.95. Found: C, 62.68; H, 4.79; N, 9.81.

General procedure for the synthesis of compounds 6a-k: A mixture of halo aldehyde (**1**, 1.0 mmol), 3-aminopyrrazole/5-aminopyrrazole (**5**, 1.0 mmol), $\text{Pd}(\text{OAc})_2$ (2.5 mol%), PPh_3 (5 mol%) and K_2CO_3 (2.1 mmol) was irradiated in a closed vessel in a Synthos 3000 microwave reactor at 700 Watt (120 °C and 14 bar) for 15 minutes. After completion of the reaction, the reaction mixture was treated with water (40 mL) and then extracted with ethylacetate (30 mL x 3). The organic portion was washed with water, dried over anhydrous sodium sulfate and the solvent was removed in vacuo to obtain a crude product which on silica gel column chromatographic purification using EtOAc/hexane as the eluent afforded compounds **6a-k**.

9-Methoxy-5a,6,7,11b-tetrahydrobenzo[h]pyrazolo[1,5-a]quinazoline (6a): Red solid, mp: 126 °C. ^1H NMR (CDCl_3 , 300 MHz) δ 9.41 (d, $J = 9.0$ Hz, 1H), 8.39 (s, 1H), 8.18 (d, $J = 2.4$ Hz, 1H), 6.98 (dd, $J = 9.0$ Hz & 2.7 Hz, 1H), 6.89 (d, $J = 2.4$ Hz, 1H), 6.73 (d, $J = 2.4$ Hz, 1H), 3.91 (s, 3H), 2.97 (s, 4H). ^{13}C NMR (CDCl_3 , 75 MHz) δ 161.6, 148.8, 143.9, 142.5, 140.0, 131.4, 119.4, 114.1, 111.5, 96.3, 55.4, 29.0, 24.1. IR (CHCl_3 , cm^{-1}): 2927, 1606, 1412, 1266, 1190, 944, 772. MS (EI, m/z): 251. Anal. calcd. for $\text{C}_{15}\text{H}_{13}\text{N}_3\text{O}$: C, 71.70; H, 5.21; N, 16.72; Found: C, 71.99; H, 5.43; N, 16.64.

9-Methoxy-2-methyl-6,7-dihydrobenzo[h]pyrazolo[1,5-a]quinazoline (6b): Gum. ^1H NMR (CDCl_3 , 300 MHz) δ 9.45 (d, J = 8.7 Hz, 1H), 8.29 (s, 1H), 6.91 (dd, J = 8.7 Hz & 2.4 Hz, 1H), 6.86 (d, J = 2.4 Hz, 1H), 6.48 (s, 1H), 3.89 (s, 3H), 2.89-2.96 (m, 4H), 2.57 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz) δ 161.4, 154.1, 150.8, 148.5, 142.4, 139.2, 131.4, 119.6, 114.7, 114.1, 111.4, 95.4, 55.4, 31.9, 29.7, 24.1. IR (CHCl_3 , cm^{-1}): 2924, 1602, 1493, 1244, 1188, 1038, 774. MS (EI, m/z): 265.1. Anal. calcd. for $\text{C}_{16}\text{H}_{15}\text{N}_3\text{O}$: C, 72.43; H, 5.70; N, 15.84; Found: C, 72.47; H, 5.75; N, 15.95.

6,7-Dihydrobenzo[h]pyrazolo[1,5-a]quinazoline (6c): Yellow solid, mp: 65 °C. ^1H NMR (CDCl_3 , 300 MHz) δ 9.41 (dd, J = 6.9 & 4.8 Hz, 1H), 8.41 (s, 1H), 8.19 (d, J = 2.4 Hz, 1H), 7.32- 7.53 (m, 3H), 6.75 (d, J = 2.4 Hz, 1H), 2.99- 2.91 (m, 4H). ^{13}C NMR (CDCl_3 , 75 MHz) δ 150.1, 149.3, 143.8, 139.8, 131.1, 129.1, 128.8, 128.1, 126.9, 126.7, 124.1, 116.9, 96.7, 28.6. IR (CHCl_3 , cm^{-1}): 2930, 1607, 1509, 1451, 1233, 1131, 765. MS (EI, m/z): 221. Anal. calcd. for $\text{C}_{14}\text{H}_{11}\text{N}_3$: C, 76.00; H, 5.01; N, 18.99; Found: C, 76.08; H, 5.31; N, 19.15.

7-(p-Tolyl)pyrazolo[1,5-a]pyrimidine (6d): Gum. ^1H NMR (CDCl_3 , 300 MHz) δ 8.52 (d, J = 4.5 Hz, 1H), 8.17 (d, J = 2.4 Hz, 1H), 7.94 (d, J = 8.1 Hz, 2H), 7.38 (d, J = 8.1 Hz, 2H), 6.89 (d, J = 4.5 Hz, 1H), 6.78 (d, J = 2.4 Hz, 1H), 2.46 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz) δ 149.9, 149.1, 146.9, 144.6, 141.6, 129.4, 129.1, 128.2, 106.9, 96.9, 29.7. IR (CHCl_3 , cm^{-1}): 2922, 1604, 1538, 1507, 1251, 1219, 1130, 808, 772. MS (EI, m/z): 209. Anal. calcd. for $\text{C}_{13}\text{H}_{11}\text{N}_3$: C, 74.62; H, 5.30; N, 20.08; Found: C, 74.74; H, 5.46; N, 19.87.

2-Methyl-7-(naphthalen-2-yl)pyrazolo[1,5-a]pyrimidine (6e): White solid, mp: 122 °C. ^1H NMR (CDCl_3 , 300 MHz) δ 8.58 (s, 1H), 8.46 (d, J = 4.5 Hz, 1H), 8.07 (d, J = 7.0 Hz, 1H), 8.05-7.52 (m, 5H), 6.88 (d, J = 4.5 Hz, 1H), 6.59 (s, 1H), 2.54 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz) δ 155.1, 150.7, 148.6, 146.2, 134.4, 132.9, 129.8, 128.9, 128.6, 128.3, 127.8, 127.7, 126.7, 125.6, 106.9, 96.4, 14.9. IR (CHCl_3 , cm^{-1}): 2925, 1601, 1532, 1505, 1352, 1259, 1208, 1067, 861, 810, 774. MS (EI, m/z): 259.1. Anal. calcd. for $\text{C}_{17}\text{H}_{13}\text{N}_3$: C, 78.74; H, 5.05; N, 16.20; Found: C, 78.82; H, 5.08; N, 16.21.

2-(4-Methoxyphenyl)-7-(naphthalen-2-yl)pyrazolo[1,5-a]pyrimidine (6f): Yellow solid, mp: 175 °C. ^1H NMR (CDCl_3 , 300 MHz) δ 8.73 (s, 1H), 8.48 (d, J = 4.3 Hz, 1H), 8.18 (d, J = 8.6 Hz, 1H), 8.01-7.89 (m, 4H), 7.61-7.54 (m, 2H), 7.02 (s, 1H), 6.99-6.94 (m, 4H), 3.84 (s, 3H). ^{13}C NMR (CDCl_3 , 75 MHz) δ 160.4, 155.9, 151.1, 148.6, 146.3, 134.4, 132.9, 130.2, 129.1, 128.4, 128.1, 127.9, 127.8, 127.7, 126.7, 125.8, 125.6, 114.2, 107.1, 92.9, 55.3. IR (CHCl_3 , cm^{-1}): 2924, 1607, 1524, 1249, 1031, 773. MS (EI, m/z): 351.1. Anal. calcd. for $\text{C}_{23}\text{H}_{17}\text{N}_3\text{O}$: C, 78.61; H, 4.88; N, 11.96; Found: C, 78.68; H, 4.79; N, 11.94.

2-Methyl-7-(thiophen-3-yl)pyrazolo[1,5-a]pyrimidine (6g): Yellow solid, mp: 112 °C. ¹H NMR (CDCl₃, 300 MHz) δ 8.64 (d, *J* = 3.8 Hz, 1H), 7.73 (d, *J* = 5.0 Hz, 1H), 7.29-7.13 (m, 3H), 6.59 (s, 1H), 2.61 (s, 1H). ¹³C NMR (CDCl₃, 75 MHz) δ 155.1, 132.5, 131.6, 131.56, 127.7, 96.1, 14.9. MS (EI, *m/z*): 215. Anal. calcd. For C₁₁H₉N₃S: C, 61.37; H, 4.21; N, 19.52; Found: C, 61.42; H, 4.28; N, 19.39.

7-(3-Nitrophenyl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile (6h): Brown solid, mp 215 °C. ¹H NMR (CDCl₃, 300 MHz) δ 8.93 (s, 1H), 8.86 (d, *J* = 4.4 Hz, 1H), 8.50 (d, *J* = 7.8 Hz, 1H), 8.48 (s, 1H), 8.41 (d, *J* = 7.8 Hz, 1H), 7.84 (t, *J* = 8.0 Hz, 1H), 7.28 (d, *J* = 6.0 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ 152.6, 147.3, 135.1, 130.9, 130.1, 126.4, 124.6, 110.0. IR (CHCl₃, cm⁻¹): MS (EI, *m/z*): 265.0. Anal. calcd. For C₁₃H₇N₅O₂: C, 58.87; H, 2.66; N, 26.41; Found: C, 58.94; H, 2.57; N, 26.47.

8-Methylpyrazolo[1,5-a]quinazoline (6i): Yellow solid, mp: 127 °C. ¹H NMR (CDCl₃, 300 MHz) δ 8.83 (s, 1H), 8.28 (s, 1H), 8.09 (d, *J* = 2.1 Hz, 1H), 7.84-7.79 (m, 1H), 7.37-7.35 (m, 1H), 6.79 (d, *J* = 2.1 Hz, 1H), 2.63 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz) δ 151.5, 145.9, 145.8, 142.6, 136.3, 128.3, 126.9, 116.5, 114.4, 99.5, 29.7. IR (CHCl₃, cm⁻¹): 2920, 1624, 1599, 1286, 868, 773. MS (EI, *m/z*): 183. Anal. calcd. for C₁₁H₉N₃: C, 72.11; H, 4.95; N, 22.94; Found: C, 72.18; H, 4.90; N, 22.81.

7-Fluoropyrazolo[1,5-a]quinazoline (6j): Gum. ¹H NMR (CDCl₃, 300 MHz) δ 8.84 (s, 1H), 8.52-8.11 (m, 1H), 8.11 (d, *J* = 2.1 Hz, 1H), 7.68-7.59 (m, 2H), 6.84 (d, *J* = 2.1 Hz, 1H). ¹³C NMR (CDCl₃, 75 MHz) δ 157.9, 150.7, 142.7, 122.9, 122.6, 117.2, 117.1, 113.1, 112.8, 100.2. IR (CHCl₃, cm⁻¹): 2923, 1560, 1244, 772. MS (EI, *m/z*): 187.0. Anal. calcd. for C₁₀H₆FN₃: C, 64.17; H, 3.23; N, 22.45; Found: C, 64.34; H, 3.20; N, 22.47.

7-Fluoro-2-methylpyrazolo[1,5-a]quinazoline (6k): White solid, mp: 130 °C. ¹H NMR (CDCl₃, 300 MHz) δ 8.75 (s, 1H), 8.39 (m, 1H), 7.61-7.51 (m, 2H), 6.61 (s, 1H), 2.55 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz) δ 159.1 (*J*_{C-F} = 244.7 Hz), 152.7, 150.3, 146.1, 132.8, 122.6 (*J*_{C-F} = 24.6 Hz), 118.9 (*J*_{C-F} = 7.8 Hz), 116.8 (*J*_{C-F} = 8.1 Hz), 112.6 (*J*_{C-F} = 22.6 Hz), 99.5, 29.5. IR (CHCl₃, cm⁻¹): 3054, 2923, 1607, 1558, 1253, 1244, 1152, 1132, 949, 826. MS (EI, *m/z*): 201. Anal. calcd. for C₁₁H₈FN₃: C, 65.66; H, 4.01; N, 20.88; Found: C, 65.74; H, 3.87; N, 20.79.

7-(3-Aminophenyl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile (6l): To a stirring solution of compound **6h** (0.5 mmol) in ethanol catalytic amount of Pd/C was added. The reaction mixture was stirred under H₂ gas for 2 hours. After completion of the reaction, the catalyst was filtered off and the solvent was removed under vacuo. The crude product thus obtained on silica gel column chromatographic purification using EtOAc/hexane (2:3) as the eluent

afforded compound **6l**. Yellow crystals, mp: 227 °C. ¹H NMR (DMSO-d₆, 500 MHz) δ 8.86 (d, *J* = 4.0 Hz, 1H), 8.85 (s, 1H), 7.45 (dd, *J* = 4.5 Hz & 2 Hz, 1H), 7.27 (s, 1H), 7.25 (d, *J* = 8.5 Hz, 1H), 7.14 (d, *J* = 8.2 Hz, 1H), 6.82 (d, *J* = 8.2 Hz, 1H), 5.47 (bs, 2H). ¹³C NMR (CDCl₃, 125 MHz) δ 154.0, 151.5, 149.0, 148.9, 147.5, 130.4, 129.6, 117.4, 117.4, 114.8, 113.9, 110.7, 81.5. IR (CHCl₃, cm⁻¹): 2917, 1446, 845, 781. MS (EI, *m/z*): 235. Anal. calcd. for C₁₃H₉N₅: C, 66.37; H, 3.86; N, 29.77; Found: C, 66.47; H, 3.89; N, 29.61.



MTT ASSAY PROTOCOL

Cellular viability in the presence of test compounds was determined by MTT-micro cultured tetrazolium assay. The cells seeded to flat bottomed 96 (1000 cells/100 µl) well plates & cultured in the medium containing 10% serum and allowed to attach and recover for 24 hours in a hid chamber containing 5% CO₂. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma catalog No M2128) was dissolved in PBS at 5 mg/mL and filtered to sterilize. Different concentrations of compounds were added to the cells. After 48 hours, stock MTT solution (10 µl) was added to the culture plate. Cells were again kept in CO₂ incubator for 2 hours. After incubation 100 µL of DMSO was added and mixed. The absorbance was read at 562 nm in a plate reader. The results were represented as percentage of cytotoxicity/viability. All the experiments were carried out in triplicates. From the percentage of cytotoxicity the IC₅₀ values were calculated.


Media used was MEM (Catalog No M0643), DPBS (Catalog No D5652), 1X antibiotic solution of 100X, (Catalog No A5955), 1% Sodium pyruvate (Catalog No.S8636), 1% Non essential amino acids (Catalog No M7145), 10% fetal bovine ser (Catalog No F2442), DMSO (Catalog No D5879), Trypsin-EDTA solution (0.25%, 2.5 g porcine trypsin and 0.2 g EDTA) (Catalog No T4049).

Reference


- (1) S. Myadaraboina, M. Alla, V. Saddanapu, V. R. Bommena and A. Addlagatta, *Eur. J. Med. Chem.* 2010, 45, 5208.







9510.001.esp







Recorded by: Dr. P.J. Saikia
Name of Sample: TBF-ET-Pz
Spectrum No.: 9536















9712.001.esp





Recorded by: Dr. P. J. Saikia
Name of Sample: Ph-CD-OH3-PZ
Spectrum No.: 9743








9338.001.esp





Recorded by: Dr. P. J. Sakin
Name of Sample: K5-DET-P2
Spectrum No.: 9365







11507.001.esp




Name of Sample : PP-40 (A)
Spectrum No : 11553




9233.001.esp





9233.001.esp




Recorded by: Dr. P. J. Saikia
Name of Sample: KS-D-Pz
Spectrum No.: 9305







Recorded by: Dr. P.J. Saikia
Name of Sample: KS-DIPH-P2
Spectrum No.: 9366




9677.001.esp




Recorded by: Dr. P.J. Saikia
Name of Sample: F-PZ
Spectrum No.: 9715





9678.001.esp





Recorded by: Dr. P. J. Saikia
Name of Sample: MC-PZ
Spectrum No.: 9714







9623.001.esp





Recorded by: Dr P.J. Saikia
 Name of Sample: TBF-NH-PZ-L
 Spectrum No.: 9508












11527.001.esp




Name of Sample : NAPH-PZ-CHO
Spectrum No : 11575





11627.001.esp




Name of sample: KS-PHOM-PZ
Spectrum No.: 11723








13763.001.esp



Sample: 292
aceto-no2-cn




10277.001.esp




10690.001.esp

8.84
8.52
8.49
8.47
8.11
8.10
7.65
7.63
7.62
7.60
7.60
7.27
6.85
6.84



-0.00




Name of Sample: F-Br-NH
Spectrum No : 10705



10962.001.esp



Sample Name: Aceto-NH2-PzCN
Spectrum No.:203



acetopznh2
359

